SCHEMBL6475923

SCHEMBL6475923

Cc1cc(Cc2ccc(F)cc2)c(=O)n2nc(C(=O)NCc3ccccc3)oc12

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 5/20 0.44
LMNA P02545 2/20 0.44
TP53 P04637 2/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483747 0.91 NR1H4 (0.44) MAPTALDH1A1LMNATP53KDM4E
SCHEMBL6476602 0.85 FPR1 (0.44) MAPTALDH1A1GAATSHRMEN1
SCHEMBL6819023 0.82 MMP13 (0.38) MAPTALDH1A1LMNATP53KDM4E
SCHEMBL6476432 0.81 ALDH1A1 (0.47) MAPTSMN1; SMN2ALDH1A1LMNATP53
SCHEMBL6819026 0.81 MAPT (0.35) MAPTSMN1; SMN2ALDH1A1LMNATP53
SCHEMBL6486582 0.79 MAPT (0.46) MAPTSMN1; SMN2ALDH1A1LMNATP53
SCHEMBL6818481 0.79 ALDH1A1 (0.45) MAPTSMN1; SMN2ALDH1A1LMNATP53
SCHEMBL6919813 0.76 PTGER4 (0.45) MAPTSMN1; SMN2LMNATP53POLB
SCHEMBL6484092 0.75 MEN1 (0.38) MAPTALDH1A1TSHRKDM4EMEN1
SCHEMBL6289333 0.74 LMNA (0.44) MAPTTHRBSMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MAPT 4485/4885THRB 4493/4885SMN1; SMN2 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.